Please assess the completion status of the following clinical trial:

Trial Title: Diabetic Retinopathy Sulodexide Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with Type 1 or Type 2 Diabetes Mellitus~* Diabetes under good control with drugs for at least 6 months (Glycosylated hemoglobin \<9% )~* Patients with 300um ≤ the thickness of retina by optical coherence tomography~* Patients with visual acuity test ≥0.4 (20/50)~* Non-proliferative (background) retinopathy assessed by fundus photography and fluorescein angiography according to Airlie House Classification and ETDRS~* Patients with non-proliferative (background) retinopathy attested by the presence of Hard exudates within grade 2 and 5~* Patients with at leat one of the following lesions: Vascular leakages, Microaneurysms, Haemorrhages, Intraretinal microvascular abnormalities (IRMA)~* Patients with controlled Arterial Blood Pressure since the last 6 months (Diastolic Blood Pressure ≤90mmHg and Systolic Blood Pressure ≤130 mmHg) with or without medication~* Patients capable of conforming to the study protocol~* Patients who have given their free and informed consent~* The ability and willingness to comply with all study procedures~Exclusion Criteria:~* Diabetic Retinopathy which is being treated with laser therapy or should be treated with laser therapy before the end of the study~* Concomitant retinal disease due to causes other than diabetic microangiopathy~* Concomitant antihypertensive treatment, unless administered at stable dosage at least 6 months before the start of the study~* Concomitant Angiotensin-converting enzyme inhibitor / Angiotensin II receptor blocker therapy, unless administered at stable dosage for at least 6 months prior to the start of the study~* Concomitant Warfarin therapy~* Patients with laser therapy or intravitreal injection(avastin,steroid) within 3 months from enrolment~* Concomitant treatment with hemorrheological, vasoactive drugs and antithrombotics except acetylsalicylic acid at stable dosage~* Patients with severe liver impairment (Child-Pugh classification C)~* Patients with severe renal insufficiency (creatinine \>2.2 mg/dl)~* Patients with severe cardiac insufficiency (New York Heart Association classes 3 - 4)~* Patients with clinical history of diathesis and haemorrhagic disease~* Individual hypersensitivity toward the product, heparin, low molecular weight heparin or heparin-like products~* Intended or ascertained pregnancy or lactation~* Participation to a trial within the past 6 months~* Surgery or trauma within the past 6 months~* Planned surgical intervention within 6 months from enrolment~* Patients unable to conform to the study protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sulodexide group (Type: ACTIVE_COMPARATOR): 50 mg of sulodexide a day will be administered by oral route (1+1 capsule/day) for 360 days
- Placebo group (Type: PLACEBO_COMPARATOR): Sulodexide placebo will be administered at the same schedule (1+1 capsule/day) and for the same lengths of time (for 360 days) as Sulodexide group

Based on this trial design, predict the completion outcome and termination type (if applicable).